Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Non-Current Assets (2020 - 2021)

SAB Biotherapeutics (SABS) has disclosed Other Non-Current Assets for 2 consecutive years, with $13.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Other Non-Current Assets rose 5471.24% year-over-year to $13.1 million, compared with a TTM value of $13.1 million through Dec 2021, up 5471.24%, and an annual FY2021 reading of $13.1 million, up 5471.24% over the prior year.
  • Other Non-Current Assets was $13.1 million for Q4 2021 at SAB Biotherapeutics, up from $235111.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.1 million in Q4 2021 and bottomed at $235111.0 in Q4 2020.